Moving iMage Technologies: Moving iMage Technologies Reschedules Q4 Call to Monday, September 28th at 11am ET

Moving iMage Technologies (MITQ) postponed its Q4 earnings release and call to September 28. The delay was to finalize financial statements. The call will include Q&A and a replay will be available.

Original reporting
Published Sep 23, 2026, 11:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MITQ
Neutral
medium confidence
Mentioned
$MITQ
Relevance
4/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$MITQNeutralLow
01

Why it matters

The rescheduling itself does not change fundamentals but may affect short‑term trading around the call.

02

Market read

Primary relevance is to MITQ shareholders awaiting earnings; no broader market move.

03

What to watch

Any pending product launches or contract wins that could be disclosed in the upcoming earnings.

Relevance 4/10Novelty 5/10Timing: pre‑market Monday Sep 28

Background

Moving iMage Technologies provides cinema audio‑visual hardware and services; the company files quarterly reports on the NYSE American exchange.

Company-level read

Ticker impact

$MITQNeutralMedium confidence
Context

Moving iMage Technologies announced it will report its FY2026 Q4 results on Sep 28, rescheduling the earnings call.

Expected impact

Minor price movement expected around the call, no directional bias.

Evidence & confidence

Rescheduling alone provides limited catalyst; impact depends on the upcoming earnings numbers.

Market effects

Minimal effect on the cinema equipment sector; peers may see slight attention.

U.S. market only, no broader regional impact.

Low global relevance.

Counterpoint

Investors could view the delay as a sign of potential earnings weakness.

Key entities

  • Moving iMage Technologies, Inc.

    Provider of cinema products and solutions.

Related articles

$MITQMed

Cinema Solutions Provider Moving iMage Technologies Progresses Toward Profitability, Trimming FY 2026 Net Loss 69% to ($297K) on Net Sales of $17.3M; Hosts…

MOVING iMAGE TECHNOLOGIES INC. (MITQ) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cinema Solutions Provider Moving iMage Technologies Progresses Toward Profitability, Trimming FY 2026 Net Loss 69% to ($297K) on Net Sales of $17.3M; Hosts Investor Call Today at 11am ET Fountain Valley, CA – September 28, 2026 – Moving iMage Technologies, Inc. (NYSE

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$YTRAMed

Yatra Online Inc (YTRA) (Q2 2027) Earnings Call Highlights: Air and Corporate Travel

Yatra Online (YTRA) reported Q2 2027 revenue from operations down 39% YoY to INR2,136M (~$22M) due to lower MICE volumes. Gross margin stayed flat at INR1,255M (~$13M). Adjusted EBITDA swung to negative INR32M (~negative $0.3M). CEO Gupta noted MICE recovery signs, TravelPro and Recap initiatives progress, and AI efficiency gains. Standalone hotels grew 20% YoY. H1 FY27 revenue declined 28% YoY to INR4,015M (~$42M).